Ceftaroline Fosamil
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Ceftaroline Fosamil |
| DrugBank ID | DB06590 |
| Brand Names (EU) | Zinforo |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.20% |
Approved Indication (EMA)
Zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: Complicated skin and soft tissue infections (cSSTI) Community-acquired pneumonia (CAP) Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | rheumatoid arthritis | 98.20% | DL |
| 2 | osteoarthritis | 98.16% | DL |
| 3 | osteoarthritis susceptibility | 97.95% | DL |
| 4 | gout | 97.48% | DL |
| 5 | pseudoachondroplasia | 97.29% | DL |
| 6 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 97.16% | DL |
| 7 | hemoglobinopathy | 97.01% | DL |
| 8 | brachyolmia | 96.98% | DL |
| 9 | acromesomelic dysplasia, Hunter-Thompson type | 96.84% | DL |
| 10 | myosclerosis | 96.71% | DL |
| 11 | brachyolmia-amelogenesis imperfecta syndrome | 96.68% | DL |
| 12 | beta-thalassemia with other manifestations | 96.53% | DL |
| 13 | hepatic porphyria | 96.49% | DL |
| 14 | partial deletion of the short arm of chromosome 16 | 96.47% | DL |
| 15 | pyruvate kinase deficiency of red cells | 96.40% | DL |
| 16 | brachydactyly-syndactyly syndrome | 96.39% | DL |
| 17 | arthropathy | 96.33% | DL |
| 18 | hemolytic anemia due to glucophosphate isomerase deficiency | 96.19% | DL |
| 19 | pyropoikilocytosis, hereditary | 96.03% | DL |
| 20 | hepatoportal sclerosis | 96.03% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.